EU clears Merck’s Keytruda for un-treated lung cancer

Patients with a certain form of lung cancer will, for the first time, be able to get treatment with Merck & Co’s immunotherapy Keytruda as a first-line of attack instead of chemotherapy, following a green light from European regulators in this setting.

The European Commission has approved Keytruda (pembrolizumab) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumour mutations.

Read Full Article Here >>